Circulating hsa-miR-5096 predicts ¹⁸F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors.

ABSTRACT: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. ¹⁸F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with ¹⁸F-FDG-PET/CT status, higher risk and lower response to PRRT.

Methods

Whole miRNOme NGS profiling was conducted on plasma samples obtained from well-differentiated advanced, metastatic,

SUBMITTER: Bocchini M 

PROVIDER: S-EPMC10242108 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature